Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8651-8660
DOI: 10.1007/s00259-026-08176-8 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.09.2026. Verfasst von Xiao Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharm…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neuroendocrine Tumors, Magnetic Resonance Imaging, Organometallic Compounds. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Capital Health Research and Development Special Project.
Abstract (Originalsprache)
PURPOSE: To compare [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors (NETs). METHODS: Forty-one patients with biopsy-proven NETs were enrolled and underwent [68Ga]Ga-DOTA-TATE PET/CT and [18F] AlF-NOTA-JR11 PET/MR. Physiological organ uptake, lesion number, maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) were compared between the two examinations. RESULTS: [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT depicted 924 and 580 lesions, respectively (p < 0.001).These included 754 and 405 liver metastases(p < 0.001), as well as 29 and 25 primary tumors (p = 0.125), respectively. The 405 liver metastases detected by both examinations were significantly larger than the 349 lesions detected only by [18F]AlF-NOTA-JR11 [median diameter, 14.00 mm (Q1, Q3: 10.00, 21,00) vs. 6.00 mm (Q1, Q3: 5.00, 9.00); p < 0.001]. No significant differences were found for the detection of lymph node metastases (p = 1.000) or bone metastases (p = 0.188). In the patient-based comparison, 76% of patients (31/41) had more lesions detected by [18F]AlF-NOTA-JR11 PET/MR than by [68Ga]Ga-DOTA-TATE PET/CT. Lesion SUVmax for [18F]AlF-NOTA-JR11 was significantly lower than that for [68Ga]Ga-DOTA-TATE in primary tumors (p = 0.002), liver metastases (p = 0.017) and bone metastases (p = 0.008), whereas no significant difference was observed in lymph node metastases (p = 0.144). [18F]AlF-NOTA-JR11 PET/MR showed higher TBR than [68Ga]Ga-DOTA-TATE PET/CT in primary tumors (p = 0.014), lymph node metastases (p = 0.034) and liver metastases (p < 0.001), with no significant difference in bone metastases(p = 0.343). CONCLUSION: [18F]AlF-NOTA-JR11 PET/MR shows lower background uptake and higher TBR for primary tumors, lymph node metastases and liver metastases. It also detected more liver metastases than [68Ga]Ga-DOTA-TATE PET/CT. These findings provide valuable evidence supporting the clinical use of [18F]AlF-NOTA-JR11 PET/MR in patients with NETs. TRIAL REGISTRATION NUMBER: 2020KT15 DATE OF REGISTRATION: 30/03/2020.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of N…
- Beijing United Imaging Healthcare Technology Development Co., Ltd, Beijing, China.
- Department of General Surgery, Peking University Third Hospital, Beijing, 100191, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Förderung
- Capital Health Research and Development Special Project
Zitieren
APA
Jin, X., Xie, Q., Ding, X., Yu, B., Zhang, Y., Su, X., Yuan, C., Lu, M., Yang, Z., & Yu, J. (2026). Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8651-8660. https://doi.org/10.1007/s00259-026-08176-8
Vancouver
Jin X, Xie Q, Ding X, Yu B, Zhang Y, Su X, et al. Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8651-8660. doi:10.1007/s00259-026-08176-8
BibTeX
@article{Jin2026,
author = {Jin, Xiao and Xie, Qing and Ding, Xiangxiang and Yu, Boqi and Zhang, Yan and Su, Xiaofan and Yuan, Chunhui and Lu, Ming and Yang, Zhi and Yu, Jiangyuan},
title = {Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8651--8660},
doi = {10.1007/s00259-026-08176-8}
}
EUVIMED